Objectives: HPC3005 is a multicentre, open-label, telaprevir trial in HCV/HIV coinfected patients with severe fibrosis or compensated cirrhosis. Methods: Patients were treated with telaprevir 750 mg every 8 h (1125 mg if on efavirenz) plus pegylated interferon-alpha (PEG-IFN, 180 μg once-weekly) and ribavirin (RBV, 800 mg/day) for 12 weeks, followed by 36 weeks of PEG-IFN/RBV. Results: Mean age was 44 years, 97/118 patients were male and all were Caucasian, 68 had severe fibrosis and 50 had cirrhosis. Seventy-eight had HCV RNA levels ≥800 000 IU/mL, 72 had HCV genotype 1a, baseline HIV RNA was <50 copies/mL in 112 patients. Overall, 114/118 patients continued antiretroviral treatment, 4 were untreated. Seventy-five patients received tenofovir and 74 emtricitabine; in addition 53 received atazanavir/ritonavir, 43 raltegravir, and 24 efavirenz. By intention-to-treat, 78 (66%) patients achieved SVR24. Nineteen discontinued telaprevir, 8 for virological endpoint, 5 for adverse events (2 anaemia, 2 rash, 1 asthenia), 5 for non-compliance and 1 withdrew consent. The most common adverse events were anaemia (36 patients), thrombocytopaenia (33), rash (26), bilirubin increase (17), and neutropenia (16). Conclusions: In this early access programme in coinfected patients with severe fibrosis or cirrhosis, 66% of patients achieved SVR. The most common adverse events were haematological. Clinical Trial Number: NCT01500616.
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients : An early access programme / A. Gori, M. Doroana, O. Chernova, J. Rockstroh, D. Banhegyi, C. Bergin, G. Verucchi, C. Liu, R. Demasi, B. Hadacek, M. Nelson. - In: JOURNAL OF INFECTION. - ISSN 0163-4453. - 71:6(2015 Dec), pp. 675-682.
|Titolo:||Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients : An early access programme|
GORI, ANDREA (Corresponding)
|Parole Chiave:||Bridging fibrosis; Cirrhosis; Coinfection; Hepatitis C; HIV; Telaprevir; Microbiology (medical); Infectious Diseases|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||dic-2015|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.jinf.2015.09.013|
|Appare nelle tipologie:||01 - Articolo su periodico|